RBC downgrades ConvaTec to “sector perform,” raises target to 320p

RBC Capital Markets downgraded ConvaTec Group (CTEC) to "sector perform" from "outperform," raising the price target to 320p from 305p due to valuation concerns after a 30% relative outperformance since the start of 2025. While RBC increased EPS estimates by 1.2% for 2025 and 1.3% for 2026, projecting a 14% compound annual EPS growth rate from 2025 to 2027, analysts believe the current valuation reflects much of the positive momentum, limiting near-term share price appreciation despite continued strong operational execution and potential longer-term upside if the company achieves mid-20s EBIT margins.

Analysis

RBC Capital Markets has recalibrated its stance on ConvaTec Group (CTEC), downgrading the stock to "sector perform" from "outperform" primarily due to valuation concerns following a significant share price appreciation of approximately 30% relative to the broader sector since the beginning of 2025. Despite this downgrade, RBC raised its price target on ConvaTec to 320p from 305p, underpinned by upward revisions to earnings forecasts; EPS estimates were increased by 1.2% for 2025 and 1.3% for 2026, with a projected 14% compound annual EPS growth rate from 2025 to 2027. RBC's analysis suggests that the current valuation, with the new 320p target based on a 22x multiple of 2026 EPS, already reflects much of the company's strong operational execution, momentum from its InnovaMatrix portfolio, and recent guidance upgrades, placing the stock in the upper half of its peer group and above its historical range, thereby limiting scope for further multiple expansion in the near term. Key risks identified include uncertainty surrounding the InnovaMatrix unit's performance, potential impacts from tariffs, and challenges in second-half margin execution. However, RBC maintains a constructive long-term outlook, contingent on ConvaTec achieving its target of mid-20s EBIT margins, which could support a 24x P/E multiple on 2027 forecasts and imply a share price of 400p by the end of 2026. An external AI-driven analysis by InvestingPro also indicated that CTEC was not among its top-ranked undervalued stocks.

Key Decisions for Investors

• Investors who have benefited from ConvaTec's recent 30% outperformance should consider the current valuation, which RBC suggests limits near-term upside, potentially warranting a review of position size.
• Monitor ConvaTec's progress on achieving mid-20s EBIT margins and the performance of its InnovaMatrix unit, as these are key catalysts for RBC's more optimistic long-term scenario of 400p per share.
• Carefully weigh the strong projected 14% compound annual EPS growth against the identified risks, including tariff impacts and margin execution, and the stock's current premium valuation relative to peers and its historical range.